Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics
  • About
    • Corporate Presentation
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • Sec Filings
    • Stock Information
      • Stock Quote & Chart
    • Shareholder Service
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us
Contact
  • About
    • Corporate Presentation
  • Pipeline
    • Overview
    • SNS-301
    • SNS-401
    • Vista
    • Presentations
  • Platform
    • Immunophage
    • Therapeutic cocktails
    • Phortress
    • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • Sec Filings
    • Stock Information
      • Stock Quote & Chart
    • Shareholder Service
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us

News

Blog Topics
  • 2018(7)
  • 2019(9)
  • 2020(7)
  • 2021(5)
  • Presentation(3)
  • Publication(16)
Recent Posts
  • SITC Safety and Efficacy
  • Refractory Head and Neck Cancer Enrollment Update
  • SITC TIP
  • Iwagami Y et al. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 2017, PMID: 28971150
  • Arab A et al. Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunol Res. 2018, PMID: 29143917
About

We are a clinical-stage immunotherapy company engaged in the discovery and development of next generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response.

Contact
Headquarters
1405 Research Blvd, Suite 125
Rockville, MD 20850
Phone No
phone

+1.240.243.8000

Boston R&D Location
Smart Labs, Seaport District
6 Tide Street
Boston, MA 02210
Email
phone

info@senseibio.com

© 2021 Sensei Biotherapeutics. All Rights Reserved.
  • Privacy Policy
Footer
Go to Top